Home / Pharma News

Pharma News

UK plans to cut drug prices by up to 20%

The UK’s Department of Health (DoH) has launched a consultation to strengthen the statutory pharmaceutical pricing scheme, which covers the prices the National Health Service (NHS) pays for brand-name drugs not covered by the voluntary Pharmaceutical Price Regulation Scheme (PPRS). The consultation is seeking views on a price cut on drug prices of between 10% and 20% to ensure the NHS continues to get good value for money.

Viagra generics hit the market in Europe

The patent on Pfizer’s blockbuster erectile dysfunction drug Viagra (sildenafil) expired on 21 June 2013 in the UK, along with several other European countries.

Nigeria needs to combat fake drugs and ageing facilities

Nigeria has ageing drug-manufacturing facilities and a problem with imports of fake drugs, according to Mr Olakunle Ekundayo, Group Managing Director, Drugfield Pharmaceuticals.

Sun Pharma looking to buy Sweden’s Meda

India-based Sun Pharmaceutical Industries (Sun Pharma) is reportedly in talks to acquire Swedish drugmaker Meda for US$5–6 billion.

Actavis makes definitive agreement with Warner Chilcott

US generic drugmaker Actavis (formerly Watson) and Irish drugmaker Warner Chilcott announced on 20 May 2013 that the two companies had entered into a definitive agreement under which Actavis will acquire Warner Chilcott in a stock-for-stock transaction valued at approximately US$8.5 billion.

Actavis in discussions to buy Warner Chilcott

US generics maker Actavis (formerly Watson) confirmed on 14 May 2013 that the company had entered into discussions to buy Irish drugmaker Warner Chilcott.

Valeant deal to acquire Actavis on hold

Drugmaker Valeant Pharmaceuticals International (Valeant) was in talks to acquire generics manufacturer Actavis for more than US$13 billion, in what would rank as one of the biggest healthcare deals this year. However, reports are that the deal is now on hold.

UK accuses GSK of delaying generics

The UK’s competition watchdog is accusing GlaxoSmithKline (GSK) of delaying the entry of generics to its antidepressant drug Seroxat (paroxetine) by paying rival companies to stay off the market.

Generics drugmakers should be held responsible for injuries

In the long saga of generics pre-emption, The New York Times is adding its opinion to the argument of whether generics makers are liable for injuries caused by their products. The newspaper believes that ‘manufacturers should bear responsibility for making sure their drugs are safe and effective’ and is urging US Congress to amend laws to allow patients to sue generics manufacturers.

Greece and Syria facing severe drug shortages

Greece and Syria are both facing severe shortages in essential medicines, but for very different reasons.

Generics News Research General

more

Biosimilars News Research General

more